Viewing Study NCT05267392

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:38 PM
Ignite Modification Date: 2026-03-01 @ 11:27 AM
Study NCT ID: NCT05267392
Status: UNKNOWN
Last Update Posted: 2022-03-04
First Post: 2021-12-13
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
Sponsor: Instituto Portugues de Oncologia, Francisco Gentil, Porto
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Small Cell Lung Cancer (NSCLC) View
None PD1/PD-L1 View
None anti-PD1/PD-L1 blockade View
None Non-Surgical Early Stage or Locally Advanced NSCLC View